Graduate Business Insights & Analytics Data Scientist – Intern @ Lilly USA

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We’re looking for people who are determined to make life better for people around the world.

Functional Overview & Responsibilities

Business Insights & Analytics Data Scientist Overview:

You will be part of a growing team of data science professionals with experience ranging across the analytical disciplines. The team’s main goal is to help our marketing, finance, and business leadership partners improve patient lives through advanced data analytics. Key responsibilities of the Business Insights & Analytics – Data Science Intern include:

Collaborating with commercial teams to identify, scope, and execute analytic efforts that answer business questions, solve business needs, and add business value. Examples include estimating marketing channel effectiveness, improving customer engagement and identifying barriers to care.
Suggesting innovations to current approaches and possible future projects
Communicating insights to empower key stakeholders to inform decision-making
Maintaining a broad understanding of sales and marketing and be fully engaged with business teams, bringing an objective voice to the table, and facilitating decisions grounded in data
Engaging with other analytics team members to review and provide feedback on the analytics work being done, and be willing to seek feedback from other team members about your own work
Staying current with respect to data science methodology, to maintain proficiency in applying new and varied methods, and to be competent in justifying methods selected

Basic Qualifications

Requirements:

Pursuing a PhD in Statistics, Economics, Computer Science, Operations Research, Finance, Mathematics or other related quantitative field.

Additional Functional Job Skills & Preference

Proficiency in at least one analytical programming tool (Python or R)
Competency in standard database concepts and ability to directly query and join tables via code (E.g.: SQL, Tidyverse, Pandas)

Research experience in one or more of the following:
- Machine Learning/Artificial Intelligence
- Non-linear Dimension reduction
- Clustering and other unsupervised techniques
- Computer Vision
- Causal AI/inference
- Time Series (multivariate and ML approaches preferred)
- Survival Analysis
- Natural Language Processing

Strong analytical skills coupled with business acumen, and an ability to think strategically in an ambiguous environment
Experience with healthcare data is a plus.
Excellent communication (written & verbal), interpersonal influencing skills and prioritization skills with attention to detail
Ability to translate technical work for business partners.

Additional Information

All interns will be considered for full-time positions based on their internship performance

Lilly arranges various intern activities including sporting events, dinners, lunch and learns, volunteer activities etc. to provide opportunities for socializing, professional development, and learning more about Lilly.
Interns will receive 1 week of paid time off during the Lilly summer shut-down (June 29th, 2026 – July 3rd, 2026
1:1 mentoring from an experienced professional in the function

Interns will receive a competitive salary and free parking at their work site, as well as access to Lilly’s LIFE fitness center, bike garage, and many other discounts
If the intern's job position requires a move from another location, Lilly will provide subsidized housing

Lilly is dedicated to helping individuals with disabilities to actively engage in the workforce, ensuring equal opportunities when vying for positions. If you require accommodation to submit a resume for a position at Lilly, please complete the accommodation request form (https://careers.lilly.com/us/en/workplace-accommodation) for further assistance. Please note this is for individuals to request an accommodation as part of the application process and any other correspondence will not receive a response.

Lilly is proud to be an EEO Employer and does not discriminate on the basis of age, race, color, religion, gender identity, sex, gender expression, sexual orientation, genetic information, ancestry, national origin, protected veteran status, disability, or any other legally protected status.

Our employee resource groups (ERGs) offer strong support networks for their members and are open to all employees. Our current groups include: Africa, Middle East, Central Asia Network, Black Employees at Lilly, Chinese Culture Network, Japanese International Leadership Network (JILN), Lilly India Network, Organization of Latinx at Lilly (OLA), PRIDE (LGBTQ+ Allies), Veterans Leadership Network (VLN), Women’s Initiative for Leading at Lilly (WILL), enAble (for people with disabilities). Learn more about all of our groups.

Actual compensation will depend on a candidate’s education, experience, skills, and geographic location. The anticipated wage for this position is

$43,000 - $110,000

Full-time equivalent employees also will be eligible for a company bonus (depending, in part, on company and individual performance). In addition, Lilly offers a comprehensive benefit program to eligible employees, including eligibility to participate in a company-sponsored 401(k); pension; vacation benefits; eligibility for medical, dental, vision and prescription drug benefits; flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts); life insurance and death benefits; certain time off and leave of absence benefits; and well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities).Lilly reserves the right to amend, modify, or terminate its compensation and benefit programs in its sole discretion and Lilly’s compensation practices and guidelines will apply regarding the details of any promotion or transfer of Lilly employees.

#WeAreLilly

About the company

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, IN

Founded

1876

Get referred to Lilly USA

See people who can refer or advise you

Simplify's Take

What believers are saying

Second-quarter 2026 revenue reached $23.0 billion, lifting full-year guidance again.
Foundayo gained roughly one-third of new oral GLP-1 patients by September 2026.
Houston's September 21, 2026 $6.5 billion plant expands domestic capacity and hiring.

What critics are saying

Lilly's August 2026 suit wave against compounders drags through 2027 and beyond.
Mounjaro and Zepbound face patent-cliff pressure starting 2036, inviting generic erosion.
Novo's September 2026 cardiovascular readouts directly attack Lilly's GLP-1 leadership and pricing power.

What makes Lilly USA unique

Foundayo launched April 1, 2026 as the only any-time oral GLP-1 pill.
Lilly owns tirzepatide, spanning Mounjaro and Zepbound, with broad obesity and diabetes demand.
2026 manufacturing buildout across Houston and Indiana protects supply against slower rivals.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Flexible Work Hours
Wellness Program

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Yahoo Finance

Nov 2nd, 2026

Musk backs Eli Lilly's "banger drugs" as it lifts 2026 revenue guidance to $91B-$92B

Eli Lilly raised its 2026 revenue guidance to $91 billion to $92 billion on October 29, its second increase in three months. A day later, Elon Musk told chief executive officer Dave Ricks on X that "Eli Lilly has some banger drugs coming out!" Third-quarter revenue rose 39% to $24.4 billion. Mounjaro and Zepbound, both tirzepatide, made up 65% of revenue in the first half of 2026. The next big drug is likely retatrutide, which produced more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial. Lilly plans to file it in the first quarter of 2027. Its legal status is unsettled. The FDA classed it as a drug, not a biologic, which would mean five years of exclusivity instead of 12. Lilly's appeal is pending.

Yahoo Finance

Nov 2nd, 2026

Eli Lilly's $19B factory spending tops $15.4B R&D for first time in 15 years

Eli Lilly now spends more on factories than on research for the first time since at least the end of 2011. Over the twelve months to September 30, 2026, capital spending hit $19.0 billion, against $15.4 billion for research and development. In the third quarter alone, the company spent $7.24 billion on capital projects and $4.25 billion on research. It a year earlier spent $9.63 billion on capital projects and $12.6 billion on research over twelve months, so research kept rising while capital spending roughly doubled. Management said new plants, including a $6.5 billion site in Houston, Texas, and another in Richmond, Virginia, support its growth outlook. Mounjaro and Zepbound together earned more than $16 billion in the quarter. Third-quarter free cash flow fell to $4.16 billion from $6.03 billion. Net debt rose to $44.6 billion from about $32.6 billion a year earlier.

Asianet News

Oct 31st, 2026

LLY, ABBV stocks hit all-time high - here's what's driving investor enthusiasm today.

LLY, ABBV stocks hit all-time high - here's what's driving investor enthusiasm today. Published: Oct 31 2026, 01:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook. * UBS said Lilly's underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative. * AbbVie's Q3 revenue rose 10.3% to $17.40 billion, driven by over 16% growth in its immunology business. * AbbVie raised its FY 2026 revenue forecast to $67.8 billion from $67.6 billion and adjusted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96. Shares of Eli Lilly (LLY) and AbbVie (ABBV) climbed to new record highs on Friday after the pharmaceutical behemoths reported stronger-than-expected third-quarter earnings and raised their full-year 2026 outlooks. LLY stock was up 3.5% at the time of writing, extending its gains to a fifth straight session. It is on track to post its biggest monthly gains since November 2025. Meanwhile, ABBV shares rose 1.6%. Wall Street sees upside for LLY after Q3 earnings beat. Analysts turned bullish on Eli Lilly (LLY) on Friday, betting on its obesity-drug leadership and expanding pipeline. Scotiabank raised its target to $1,605 from $1,300 and held an 'Outperform' rating, expecting Lilly to maintain its obesity-market dominance through 'next-generation products' and acquisitions. Truist lifted its target to $1,612 from $1,376, and maintained a 'Buy' rating. The firm said Lilly currently has only about 10% market penetration in obesity, and expansion of its incretin franchise and pipeline will cement its dominance in "diabesity" for years to come. On Thursday, Lilly reported a 39% increase in Q3 revenue to $24.4 billion, while adjusted earnings rose 7% to $7.48 per share. Mounjaro sales surged 65% to $10.72 billion, while Zepbound revenue rose 49% to $5.35 billion. Lilly also raised its 2026 revenue outlook to $91 billion-$92 billion from $85 billion-$87 billion. However, the company trimmed its bottom-line guidance to $35-$36 per share from $35.5-$36.5 per share. UBS said Lilly's underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative. Retail sentiment surrounding LLY on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier. The stock has gained more than 31% so far in 2026. AbbVie raises FY26 outlook. AbbVie reported better-than-expected Q3 earnings on Friday, driven by strong growth in its immunology business. Revenue rose 10.3% to $17.40 billion, beating Wall Street's estimates of $17.34 billion, according to Fiscal.ai. Adjusted earnings more than doubled to $3.82 per share, exceeding consensus estimates of $3.77 per share. Immunology revenue increased 16.3%, with Skyrizi, its autoimmune drug for psoriatic arthritis and Crohn's disease, among others, generating $5.78 billion. Rinvoq, prescribed for inflammatory conditions including rheumatoid arthritis and eczema, saw sales surge nearly 24%. AbbVie also raised its FY 2026 revenue forecast to $67.8 billion from $67.6 billion and adjusted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96. In a call with analysts, chief scientific officer Roopal Thakkar said the company is interested in expanding its obesity-treatment pipeline, according to The Fly. Meanwhile, retail sentiment for ABBV on Stocktwits remained 'neutral' over the past 24 hours. The stock has gained about 29% in 2026. For updates and corrections, email newsroom[at]stocktwits[dot]com< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Yahoo Finance

Oct 30th, 2026

Eli Lilly's Q3 revenue jumps 39% as tirzepatide's $16.1B outsells Novartis and GSK

Eli Lilly's third-quarter revenue rose 39% year on year, driven by its obesity and diabetes drugs, and the company raised its 2026 revenue outlook for the fourth time this year. Tirzepatide brands Mounjaro and Zepbound brought in $10.7 billion and $5.4 billion respectively, about $16.1 billion in total. That is more than the total quarterly revenue of Novartis, GSK, and Bristol Myers Squibb. Mounjaro sales grew 65% and Zepbound 59%. Growth slowed from 48% in the second quarter, largely because of pricing pressure. Lilly now expects 2026 revenue of $91 billion to $92 billion, up from $85 billion to $87 billion. Citi analysts called it "another exceptional quarter" and named Lilly their favourite large biopharma company.

Finanzen.net

Oct 29th, 2026

Eli Lilly stock jumps: company raises revenue target again.

Eli Lilly stock jumps: company raises revenue target again. October 29, 2026, 6:02 p.m. The pharmaceutical company Lilly can continue to rely on the weight-loss drug Zepbound and the diabetes drug Mounjaro. Both blockbusters drove growth in the third quarter as well, with billions in revenue. As a result, the US manufacturer performed better than expected in the quarter. In view of persistently high demand, CEO David Ricks once again significantly raised the company's revenue forecast for the year. In early US trading, the stock rose 8 percent to a record level. For 2026, the company now expects revenue to rise to 91 to 92 billion US dollars (around 81.7 to 82.6 billion euros), after just over 65 billion in 2025, Lilly announced in Indianapolis. At the previous forecast increase in August, CEO Ricks had still projected revenue of 85 to 87 billion dollars for this year. By contrast, the company slightly lowered its annual target for adjusted earnings per share (EPS) by half a dollar at both ends: it now expects an increase to 35 to 36 dollars per share. The reason for the slight cut was said to be charges for acquired development and research projects. In the third quarter, Lilly increased revenue by 39 percent to 24.4 billion dollars. Analysts had expected 22.5 billion on average. The diabetes drug Mounjaro brought in 10.7 billion dollars, while the weight-loss treatment Zepbound brought in 5.3 billion. Both medications exceeded market expectations. The still relatively new weight-loss pill Foundayo, however, fell short of expectations. It generated 184 million dollars in the quarter, while analysts had expected almost 50 million dollars more. The once-daily medication competes with the weight-loss pill Wegovy from Danish rival Novo Nordisk. Net profit rose by just over 15 percent in the quarter to around 6.5 billion dollars. The increase in adjusted earnings per share was smaller by comparison at seven percent to 7.48 dollars, as high research costs weighed. However, analysts had even expected a decline here. The booming business with obesity drugs has made Lilly the world's most valuable pharmaceutical company and given the company financial flexibility for increasingly ambitious expansion. To secure growth in the long term, the company - like competitor Novo Nordisk - is working on additional weight-loss agents, among other things. This includes a new generation of treatments that are more effective or have fewer side effects. One focus is the experimental agent retatrutide, which is still being clinically tested and could offer greater weight loss than previous treatments. In addition, Lilly is currently opening up new areas such as women's health and psychedelic substances. At the same time, competition and price pressure in the weight-loss drug market are intensifying, partly because Novo Nordisk is trying to win back lost market share. Eli Lilly stock was temporarily up 6.38 percent at 1,370.55 US dollars in NYSE trading. /tav/nas/jha/ Indianapolis (dpa-AFX) Selected leveraged products on Eli Lilly. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on Eli Lilly. | Name | leverage | knock-out | issuer | | Turbo long on Eli Lilly | 4.99 | 1,094.61 | Morgan Stanley | | Turbo long on Eli Lilly | 4.96 | 1,089.44 | Morgan Stanley | | Turbo long on Eli Lilly | 4.94 | 1,086.49 | Morgan Stanley | | Turbo long on Eli Lilly | 4.94 | 1,086.72 | Morgan Stanley | | Mini future long on Eli Lilly | 4.84 | 1,134.19 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR199K, MR199J, MR0JMR, MR0FUN, MR81FX. Please also note the further information** on this advertisement. Risk note: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.

Lilly USA

Graduate Business Insights & Analytics Data Scientist – Intern

About the job

About the company

Get referred to Lilly USA

Simplify's Take

What believers are saying

What critics are saying

What makes Lilly USA unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth